Table 2.

Comparison of cohorts

Variables	TERT promoter mutation		P-value
	No (n = 121)	Yes (n = 12)
Sex (n = 133)			0.76*
Male	78 (64.5)	7 (58.3)
Female	43 (35.5)	5 (41.7)
Age at time of surgery (y) (n = 133)	56.1 ± 16.5	52.9 ± 15.8	0.52†
Spinal Level (n = 132)			0.10*
Mobile	46 (38.0)	1 (9.1)
Fixed	75 (62.0)	10 (90.9)
Ethnicity (n = 115)			0.39*
Non-caucasian	16 (15.4)	3 (27.3)
Caucasian	88 (84.6)	8 (72.7)
Adjuvant Therapy Given (n = 131)			0.34*
No	77 (64.7)	10 (83.3)
Yes	42 (35.3)	2 (16.7)
Timing of Chemotherapy (n = 130)			1.00*
Preop	8 (6.8)	1 (8.3)
Postop	4 (3.4)	0 (0.0)
Both	6 (5.1)	0 (0.0)
Neither (no chemo)	100 (84.8)	11 (91.7)
Timing of Radiation Therapy (n = 131)			0.28*
Preop	9 (7.6)	2 (16.7)
Postop	20 (16.8)	0 (0.0)
Both	4 (3.4)	0 (0.0)
Neither (no radiation)	86 (72.3)	10 (83.3)
Tumor Grade (n = 133)			1.00*
Low (I)	75 (62.0)	8 (66.7)
High (II)	46 (38.0)	4 (33.3)
Enneking Appropriateness (n = 125)			0.49*
EA	75 (65.2)	8 (80.0)
EI	40 (34.8)	2 (20.0)
Local Recurrence at 10 Years Postoperative (n = 130)			0.75*
No	77 (65.3)	9 (75.0)
Yes	41 (34.7)	3 (25.0)
Survival at 10 Years Postoperative (n = 133)			0.01*
Alive	74 (61.2)	12 (100.0)
Dead	47 (38.8)	0 (0.0)

Data are presented as N (%) or mean ± standard deviation; EA: Enneking appropriate, EI: Enneking inappropriate.

*Fisher’s exact test,^†Student’s t-test